These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 3601998)

  • 1. Preclinical safety of biotechnology products intended for human use. Proceedings of a satellite symposium of the IV International Congress of Toxicology. Tokyo, Japan, July 26, 1986.
    Prog Clin Biol Res; 1987; 235():1-213. PubMed ID: 3601998
    [No Abstract]   [Full Text] [Related]  

  • 2. Preclinical safety of biotechnology products intended for human use: government regulatory position in the Federal Republic of Germany.
    Bass R; Scheibner E; Schnieders B
    Prog Clin Biol Res; 1987; 235():31-48. PubMed ID: 3602000
    [No Abstract]   [Full Text] [Related]  

  • 3. Proceedings of a satellite symposium on toxicity testing of industrial compounds. July 26, 1986, Tokyo, Japan.
    J Toxicol Sci; 1987 May; 12(2):165-288. PubMed ID: 3625811
    [No Abstract]   [Full Text] [Related]  

  • 4. Biotechnology products intended for human use, toxicological targets and research strategies.
    Zbinden G
    Prog Clin Biol Res; 1987; 235():143-59. PubMed ID: 2440056
    [No Abstract]   [Full Text] [Related]  

  • 5. The VIth UOEH International Symposium and the IIIrd COMTOX on bio- and toxicokinetics of metals. Satellite symposium of the IVth International Congress of Toxicology. July 27-31, 1986, Kitakyushu City, Japan. Proceedings.
    J UOEH; 1987 Mar; 9 Suppl():1-235. PubMed ID: 3602741
    [No Abstract]   [Full Text] [Related]  

  • 6. New concepts and developments in toxicology. Proceedings of the Fourth International Congress of Toxicology. Tokyo, Japan, July 21-25, 1986.
    Dev Toxicol Environ Sci; 1986; 12():1-411. PubMed ID: 3829953
    [No Abstract]   [Full Text] [Related]  

  • 7. Species selection for safety evaluation of biotechnology products.
    Hobson WC; Fuller GB
    Prog Clin Biol Res; 1987; 235():55-71. PubMed ID: 3602001
    [No Abstract]   [Full Text] [Related]  

  • 8. Safety evaluation of biotechnology derived products.
    Galbraith WM
    Prog Clin Biol Res; 1987; 235():3-14. PubMed ID: 3474670
    [No Abstract]   [Full Text] [Related]  

  • 9. The use of hematologic parameters in applying the principles of toxicity testing to biotechnology products.
    Payne BJ
    Prog Clin Biol Res; 1987; 235():107-20. PubMed ID: 3601999
    [No Abstract]   [Full Text] [Related]  

  • 10. Development of preimplantation embryos and their environment. Proceedings of a satellite symposium of the 8th International Congress of Endocrinology. Kyoto, Japan, July 14-16, 1988.
    Prog Clin Biol Res; 1989; 294():1-474. PubMed ID: 2726957
    [No Abstract]   [Full Text] [Related]  

  • 11. Abstracts. Fourth International Congress of Toxicology. Tokyo, Japan, 21-25 July 1986.
    Toxicol Lett; 1986; 31 Suppl():1-261. PubMed ID: 3726900
    [No Abstract]   [Full Text] [Related]  

  • 12. The preclinical development of biotechnology-derived pharmaceuticals: the PMA perspective. Pharmaceutical Manufacturers Association.
    Stoll RE
    Prog Clin Biol Res; 1987; 235():169-71. PubMed ID: 3474669
    [No Abstract]   [Full Text] [Related]  

  • 13. International Workshop on the Use of Pharmacological Methods in Safety-Evaluation of New Drugs, 1977. Proceedings.
    Pharmacol Ther B; 1979; 5(1-3):1-605. PubMed ID: 493303
    [No Abstract]   [Full Text] [Related]  

  • 14. Global perspective on specifications for biotechnology products--perspective from Japan.
    Hayakawa T
    Dev Biol Stand; 1997; 91():15-23. PubMed ID: 9413678
    [No Abstract]   [Full Text] [Related]  

  • 15. [Science of evaluating the characteristics, quality and safety of biotechnological products: RDNA-derived products, cell culture technology-derived products, gene therapy products, cellular therapy products, and transgenic animal-derived protein products and cellular products].
    Hayakawa T
    Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 1999; (117):1-38. PubMed ID: 10859934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conclusions of the satellite symposium of the Eurotox '91 Congress on Safety Aspects of Biotechnology-Derived Drugs.
    Hum Exp Toxicol; 1992 Sep; 11(5):369-72. PubMed ID: 1358153
    [No Abstract]   [Full Text] [Related]  

  • 17. Minimum safety requirements for preclinical testing.
    Dorner F; Barrett PN; Schwartz HP; Eibl H
    Dev Biol Stand; 1993; 81():245-52. PubMed ID: 8174809
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of protein safety in the context of agricultural biotechnology.
    Delaney B; Astwood JD; Cunny H; Conn RE; Herouet-Guicheney C; Macintosh S; Meyer LS; Privalle L; Gao Y; Mattsson J; Levine M;
    Food Chem Toxicol; 2008 May; 46 Suppl 2():S71-97. PubMed ID: 18348900
    [TBL] [Abstract][Full Text] [Related]  

  • 19. International Conference on Harmonisation; guidance on viral safety evaluation of biotechnology products derived from cell lines of human or animal origin; availability--FDA. Notice.
    Fed Regist; 1998 Sep; 63(185):51074-84. PubMed ID: 10185809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical safety evaluation of monoclonal antibodies.
    Lynch CM; Grewal IS
    Handb Exp Pharmacol; 2008; (181):19-44. PubMed ID: 18071940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.